Professor Yair Reisner, Ph.D

Chair, Cell Source Scientific Advisory Board

Head of Stem Cell Research, Department of Stem Cell Transplantation & Cell Therapy 

M.D. Anderson Cancer Center
Houston, Texas

Career Highlights

  • Selected by the World Technology Network in 2003 as one of the “TOP FIVE PEOPLE in the field of Health and Medicine whose work is of the GREATEST LIKELY LONG-TERM SIGNIFICANCE”

  • Mismatched Bone Marrow Transplant Pioneer (1980)

  • Inventor of Veto Cell Technology

  • 2019 Recipient of the EMET Prize in Life Sciences in Israel

  • 2018 Recipient of the DKMS Mechtild Harf Science Prize (awarded for work on immune tolerance)

Pioneered Donor Mismatched Bone Marrow Transplants

  • Together with collaborating physicians at Memorial Sloan Kettering performed the first successful mismatched BMT in a “Bubble Boy” with severe combined immunodeficiency disease (SCID)
  • Scientific advisor for Russian Ministry of Health following Chernobyl accident
  • Developed and introduced together with Prof. M. Martelli T-Cell depleted mismatched “Megadose” BMT for leukemia patients

Pre-Eminent Israeli Immunology Research Scientist

  • Former Head of Immunology at Weizmann Institute of Science
  • Former Head of Gabrielle Rich Center for Transplantation Biology Research
  • Henry Drake Professorial Chair of Immunology

International Scope Of Research Collaboration

  • Principal Investigator, Professor, Stem Cell Transplantation, Reisner Laboratory at MD Anderson Cancer Center, Houston, TX
  • Head of Stem Cell Research, Department of Stem Cell Transplantation & Cell Therapy, MD Anderson Cancer Center, Houston, TX
  • Memorial Sloan-Kettering Cancer Center, NYC
  • Columbia University, NYC
  • Skirball Institute Of Biomolecular Medicine, NYU Medical Center, NYC
  • Dana Farber Cancer Institute, Harvard University, Boston
  • Former President of Israeli Stem Cell Society

Involved in Key Immunology and Transplantation Journals and Advising Bodies

  • Deputy Editor of Bone Marrow Transplantation Journal
  • Member of European Bone Marrow Transplantation Society
  • American Society of Hematology Committee on Transplantation
  • California Institute for Regenerative Medicine

Collaborative Partnerships

Cell Source is collaborating with top-tier scientists and institutions such as Dr. Zelig Eshhar, the inventor of CAR-T therapy, and the MD Anderson Cancer Center, the world leader in bone marrow transplants and immunology.

Product Pipeline

Developed by Dr. Yair Reisner and licensed exclusively from the Weizmann Institute of Science, Cell Source’s patent portfolio consists of six major international patent families covering our range of innovative therapies and protocols.

Scientific Publications

Cell Source’s scientific leadership, allogeneic HSCT protocols, and Veto Cell technologies has been featured and discussed in immunology’s leading publications.

Scientific Advisory Board

Cell Source’s Scientific Advisory Board features leading immunologists, researchers, and doctors from across the globe.

Subscribe to Cell Source’s Newsletter

    INVESTOR ALERTS. PRESS RELEASES. INDUSTRY & COMPANY NEWS.

    Get the latest Cell Source news and updates, delivered right to your inbox.